Cruse Michael 4
4 · Reneo Pharmaceuticals, Inc. · Filed Aug 31, 2022
Insider Transaction Report
Form 4
Cruse Michael
Senior VP-Corporate Operations
Transactions
- Purchase
Common Stock
2022-08-29$3.24/sh+1,140$3,694→ 1,140 total(indirect: By Trust) - Purchase
Common Stock
2022-08-30$3.16/sh+975$3,081→ 31,758 total - Purchase
Common Stock
2022-08-31$3.21/sh+3,212$10,307→ 6,197 total(indirect: By Trust) - Purchase
Common Stock
2022-08-29$3.24/sh+83$269→ 30,783 total - Purchase
Common Stock
2022-08-30$3.19/sh+1,845$5,893→ 2,985 total(indirect: By Trust)
Footnotes (5)
- [F1]Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on June 8, 2022.
- [F2]By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust.
- [F3]The weighted average purchase price for the transaction was $3.16. The shares were purchased at a range of prices between $3.11 and $3.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F4]The weighted average purchase price for the transaction was $3.1938. The shares were purchased at a range of prices between $3.16 and $3.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F5]The weighted average purchase price for the transaction was $3.209. The shares were purchased at a range of prices between $3.19 and $3.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.